REG - Renalytix PLC - Total Voting Rights

RenalytixAnnouncement

30/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240830:nRSd2021Ca&default-theme=true

RNS Number : 2021C  Renalytix PLC  30 August 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Total Voting Rights

 

LONDON and NEW YORK, 30 August 2024 - Renalytix plc
(http://www.renalytix.com/)  (NASDAQ: RNLX) (LSE: RENX) announces that at
today's date, the Company's total issued share capital is 165,925,513
Ordinary Shares of £0.0025 each in the capital of the Company ("Ordinary
Shares"). Each Ordinary Share carries the right to one vote at a general
meeting of the Company. The Company does not hold any Ordinary Shares in
treasury.

 

The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the share capital
of the Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

 

 Renalytix plc                                    www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                            Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)      Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                    Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                              Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                                  (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings / Charlotte Edgar  Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

 CapComm Partners
 Peter DeNardo                                    Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(https://www.globenewswire.com/Tracker?data=ThoNM1PDWeVIxIN1XNvxXoh0EK3Og6d0k06ZfN9GrAjS1_QubydWs_nD7MTPteCUCpzWMT-T9VtSxqrwDhSDHeCPMgeDBf4ZA-6KeA6aJT4=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQKCBPNBKDBFB